Indeed, depletion of CD56-positive immune effectors cells by treatment with lorvotuzumab entails a risk of infection; infection-related deaths were observed with this antibody-drug conjugate in a clinical trial of patients with small cell lung cancer (87, 91). Here, NCAM1 is linked to infection.